Business Wire

Juniper Networks® Partners with Shaare Zedek Medical Center to Accelerate Digital Transformation with Automated Data Center

8.3.2023 10:00:00 EET | Business Wire | Press release

Share

Juniper Networks, (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Shaare Zedek Medical Center, Jerusalem’s largest and fastest growing multi-disciplinary medical center, has embarked on total digital transformation of operations to provide superior experiences and exceptional care to its patients using Juniper’s data center solutions.

Shaare Zedek is a leading research and teaching hospital, running 30 departments and 70 outpatient clinics, which provide innovative treatments and therapies to one million patients per year. The hospital is also a model for large-scale emergency medicine and a leader in applying AI to patient care. Using Juniper® technology, the hospital built state-of-the-art data centers on its two campuses to ensure the availability of life-critical systems and applications for uninterrupted patient care and robust data analysis to guide the best courses of treatment.

News Highlights:

  • Shaare Zedek uses the Juniper Apstra software to automate data center network operations, which leads to improved patient experiences. Apstra assures the network is running as intended and alerts the IT team if brownouts or deviations occur. The IT team also uses Apstra to manage changes, maintenance and updates.
  • With Juniper Apstra software, Shaare Zedek has been able to deploy its network fabric faster, guarantee data center uptime with network visibility and automation, streamline network operations, resolve issues more quickly and reduce total cost of ownership for its data center network.
  • The hospital operates 24x7 and cannot shut down the data center for maintenance to switches, clusters, etc. With Juniper Apstra, Shaare Zedek can fully automate changes in real time and assure continuous operations.
  • The Juniper Networks® QFX5120 Switches form the data center network fabric, delivering 100-Gbps of capacity to support clinical and administrative applications and massive data stores.
  • Shaare Zedek worked with Oasis Technologies, a Juniper Elite Plus partner, to create the optimal data center architecture, working on the design, validation and testing to ensure that the Juniper solutions met Shaare Zedek’s strategic operational and technical goals.

Supporting Quotes:

“Digital health is transforming patient care at Shaare Zedek. Our data center operations must ensure the continuous availability of our life-critical systems and applications. Juniper provides the foundation of our reliable data center with next-level automation that assures best practice and consistency, to intent from initial design to everyday operations.”

- Shimi Ben Baruch, Vice President & Chief Technology Officer, Shaare Zedek Medical Center

“The network plays a vital role in keeping a modern organization healthy. It allows organizations to scale and support new applications and technologies that can assist in driving better patient outcomes and experiences. Juniper Apstra provides high performance technologies for Shaare Zedek Medical Center to ensure that it is fully prepared for continued digital acceleration.”

- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks

Additional Resources:

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Pelin Murphy
Juniper Networks
+44 (0) 1372 385 686
pelin@juniper.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio

The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release

The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i

Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release

Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release

Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye